PROTON RADIATION THERAPY RESEARCH

质子放射治疗研究

• 批准号: 7691834
• 负责人: THOMAS F DELANEY
• 金额: $ 238.42万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7691834
• 关键词: PROTON; RADIATION; THERAPY; RESEARCH

DESCRIPTION (provided by applicant): Objectives and Specific Aims Any tumor cell can be eradicated with a sufficiently high dose of radiation; conversely, any normal tissue can be injured with sufficient dose to a given volume. The challenge for clinicians is to deliver the appropriate dose to only those tissues containing tumor. Proton radiation fields, with no exit beyond the target, deliver less radiation to normal tissues than comparable photon (x-ray) fields. This improves the therapeutic ratio (of cure probability to complication risk) because irradiation of normal tissue does not benefit the patient. We have treated nearly 7,000 cancer patients with proton therapy at the Harvard Cyclotron and Francis H. Burr Proton Therapy Center (FHBPTC) since 1974. We have achieved significant gains in clinical outcomes for a number of disease sites including chondrosarcomas and chordomas of the skull base and cervical spine (95% and 50% local control, respectively), paranasal sinus tumors (82% local control), ocular melanoma (97% local control), and prostate cancer (80% biochemically disease-free). At the FHBPTC, we have been able to expand the range of diseases treated to include pediatric malignancies at nearly any anatomic site including craniospinal axis treatment under anesthesia, nasopharyngeal carcinoma, lung and hepatocellular tumors under respiratory gating, and pelvic and retroperitoneal sarcomas. We believe that research in this field can further iimprove our utilization of the proton beam in the clinic to enhance treatment outcome. We hypothesize that, mainly through the use of advanced imaging technology, we can deliver higher precision proton therapy to further improve target coverage and/or reduced dose to nearby critical structures. We propose 3 integrated projects (1)Clinical Utilization of the Physical Advantages of Proton Therapy, (2)Optimizing the Use of Protons in the Clinic, and (3) Morbidity Reduction with Proton Radiation Therapy to test this hypothesis. The specific aims of the projects are to develop dose guided proton therapy techniques including PET/CT imaging to measure the activation of positron emitters through the proton beam, to control range in the presence of organ motion, and to advance beam delivery strategies for intensity modulated proton therapy to further improve therapeutic ratio. In selected clinical sites where tumor closely invests normal tissue, morbidity reduction with targetted biologic agents will also be explored.

描述（申请人提供）：目标和特定目的 任何肿瘤细胞都可以用足够高剂量的辐射消除。相反，任何正常的组织都可以通过足够剂量损伤给定的体积。临床医生面临的挑战是仅向含有肿瘤的那些组织提供适当的剂量。与可比光子（X射线）磁场相比，质子辐射场没有出口以外的出口向正常组织提供的辐射较少。这提高了治疗比率（治愈概率与并发症风险），因为正常组织的照射不会使患者受益。 自1974年以来，我们已经在哈佛回旋体和弗朗西斯·H·伯尔质子治疗中心（FHBPTC）治疗了近7,000名癌症患者。我们已经在许多疾病部位的临床结局取得了显着增长，包括软骨瘤和脑甲状腺肿的许多疾病症状和骨spine spine spine and caran shirus and caran sinrus和95％的par症（95％），相应地相应地（相应地）对照），眼部黑色素瘤（局部对照97％）和前列腺癌（80％生化性疾病）。在FHBPTC上，我们已经能够扩大治疗的疾病范围，以包括在麻醉下，包括麻醉，鼻咽癌，肺癌，肺和肝细胞细胞肿瘤的几乎所有解剖部位的儿科恶性肿瘤。 我们认为，该领域的研究可以进一步促进我们对诊所中质子束的利用，以增强治疗结果。我们假设，主要通过使用先进的成像技术，我们可以提供更高的精度质子治疗，以进一步改善目标覆盖率和/或减少对附近关键结构的剂量。我们提出了3个综合项目（1）质子治疗的物理优势的临床利用，（2）优化在诊所中质子的使用，以及（3）通过质子放射治疗来降低质子的发病率来检验该假设。项目的具体目的是开发剂量引导的质子疗法技术，包括PET/CT成像，以测量正电子发射器通过质子束的激活，以在器官运动的存在下控制范围，并提高强度调节质子治疗的束递送策略，以进一步提高治疗率。在肿瘤密切投资正常组织的选定临床部位中，还将探索靶向生物学剂的发病率降低。